 |
| Robert F. Kennedy Jr.’s Tenure Threatens U.S. Vaccine Industry Without a Ban |
The United States, long the world’s vaccine superpower, is seeing its dominance wane rapidly under Robert F. Kennedy Jr., the country’s new Health and Human Services Secretary and a leading figure in the anti-vaccine movement. While Kennedy and the Trump administration haven’t outlawed vaccines, their policy overhaul is destabilizing America’s vast immunization network potentially eliminating vaccines not by decree, but by suffocating the ecosystem that sustains them.
U.S. Policy Shifts Undermine Vaccines
Historically, the U.S. has anchored the global vaccine market, purchasing more than a third of the world’s vaccines and funding innovation at rates unmatched elsewhere. Federal recommendations and investments created a stable, lucrative market, attracting manufacturers despite the inherent risks and costs: vaccines, unlike drugs, must be extremely safe, are sold cheaply, and are used infrequently, all of which hinder profits. This delicate balance is now unraveling.
Since taking office, Kennedy’s HHS has made sweeping changes. Top vaccine experts have been fired, regulations tightened, and broad government recommendations scaled back. The administration cut off U.S. participation in the international Gavi vaccine initiative, and stopped hundreds of federal contracts and grants, depriving companies of key funding Moderna alone lost over $700 million targeted for pandemic-flu shot research. Public statements from the department stress a renewed emphasis on individual doctor-patient decisions over national public health directives.
Companies Retreat Amid Regulatory Uncertainty
The fallout has been swift. Vaccine companies, facing erratic U.S. policies and falling demand, are laying off workers and carving up vaccine divisions. Biotech firm CSL partly blames the turmoil for slumping profits, after the CDC discouraged two of its thimerosal-containing flu shots, even refuting years of data about the preservative’s safety. As advisory panels stacked with vaccine skeptics eye further restrictions including childhood immunizations against measles, chickenpox, and hepatitis experts warn demand could become unpredictable, crushing innovation.
Biotech start-ups, most vulnerable to financial shocks, may exit the sector entirely, further contracting the market. Rajeev Venkayya, former head of Takeda Pharmaceuticals’ vaccine unit, notes that even before these changes, vaccines were a precarious industry. “It’s just become that much harder,” says MIT economist Andrew Lo.
Legal and Financial Risks Add to the Crisis
Besides cutting funding, the administration threatens to worsen manufacturers’ legal exposure. Kennedy may terminate pandemic-era waivers shielding COVID-19 vaccine makers from lawsuits and has expressed interest in altering the Vaccine Injury Compensation Program (VICP) possibly adding autism as a compensable injury, despite overwhelming evidence against any vaccine link. Experts fear such changes could trigger a wave of litigation, reminiscent of the 1980s crisis that nearly collapsed the U.S. vaccine market, and prompt further exits.
Looming Shortages and a Precarious Future
Even a handful of company withdrawals could devastate U.S. vaccine access. For several crucial shots HPV, varicella, rotavirus only one or two manufacturers remain. Experts recall how, in 2004, contamination at one factory halved the U.S. flu vaccine supply overnight. As the nation’s vaccine infrastructure is dismantled, restarting production will only get harder and slower. A diminished market also weakens readiness for future pandemics: quick COVID-19 vaccine development depended on government funding and market confidence, both now in jeopardy.
Though most Americans still support vaccines, the country could soon face shortages not due to law, but to failed policy. As the U.S. vaccine foundation crumbles, the risk grows that Americans who want shots won’t be able to get them.
More:
1) AAP and CDC Clash Over COVID-19 Vaccines for Young Children